#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Parents and young patients who view occasional THC use as low-stakes should understand that the adolescent brain processes cannabinoids differently than an adult brain, and even limited exposure during developmental years can have measurable effects on mood regulation, memory, and long-term mental health trajectory.
Cannabis use during adolescence and young adulthood intersects with critical windows of neurodevelopmental maturation, particularly in the prefrontal cortex and limbic system, where endocannabinoid signaling plays a foundational regulatory role. Even casual or infrequent THC exposure during these years carries a distinct risk profile compared to adult use, including associations with altered executive function, increased vulnerability to anxiety and mood disorders, and in genetically susceptible individuals, elevated risk for psychosis-spectrum conditions. The developing brain is not simply a smaller adult brain, and the assumption that recreational or experimental use is consequence-free in young people is not supported by the neurobiological evidence.
“Calling teenage THC use “dabbling” is a framing problem because casual language obscures serious neurodevelopmental biology at exactly the age when it matters most.”
🧠 Dr. O’Shea highlights a critical developmental window during adolescence and young adulthood when the brain remains actively maturing, particularly in areas governing impulse control, memory, and decision-making.
🧠 The evidence suggests THC exposure during these formative years may interfere with normal neurodevelopmental trajectories, with potential impacts on cognitive function and educational outcomes that warrant careful consideration.
🧠 While some young people experiment with cannabis regardless of medical guidance, clinicians should emphasize the neurobiological risks specific to this age group and discuss harm reduction strategies when use occurs.
⚠️ A balanced discussion of efficacy versus safety is essential, as therapeutic applications in select adolescent cases (such as chemotherapy-related nausea) differ substantially from recreational or non-indicated use.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: